INSP — Inspire Medical Systems, Inc. stock price, charts and financials

Latest market price

64.14

+11.92+22.83%

Overview Short InterestFilings

INSPQT44Inspire Medical Systems, Inc.·NYSE

Overview Short InterestFilings

64.14+22.83%

Earnings

Up 22.8% — Q2 2026 earnings beat estimates (EPS +136%, revenue +2%) with raised full-year 2026 guidance and strategic growth plan.

High confidence

Loading chart...

Signal & projected range

Falling wedge — reversalHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

NVCR+6.20%$16.27 ENOV-1.78%$30.86 ATEC+1.97%$10.35 CNMD-2.82%$50.40 BFLY+7.18%$8.81 IART+0.11%$17.90 TNDM+0.45%$20.20 AXGN+0.50%$45.96

Snapshot

Index	-	P/E	14.29	EPS (ttm)	4.49	Insider Own	2.38%	Shs Outstand	28.81M	Perf Week	23.42%

Market Cap	1.85B	Forward P/E	47.74	EPS next Y	1.34	Insider Trans	-0.59%	Shs Float	27.17M	Perf Month	29.71%

Enterprise Value	1.59B	PEG	0.47	EPS next Q	-	Inst Own	-	Short Float	15.99%	Perf Quarter	16.96%

Income	131.00M	P/S	2.02	EPS this Y	-75.09%	Inst Trans	-	Short Ratio	3.77	Perf Half Y	-12.68%

Sales	916.00M	P/B	2.33	EPS next Y	20.12%	ROA	14.39%	Short Interest	4.34M	Perf YTD	-30.46%

Book/sh	27.49	P/C	6.51	EPS next 5Y	30.41%	ROE	17.98%	52W High	147.04 -56.38%	Perf Year	-49.14%

Cash/sh	9.86	P/FCF	14.96	EPS past 3/5Y	-	ROIC	6.24%	52W Low	38.91 64.84%	Perf 3Y	-77.78%

Dividend Est.	-	EV/EBITDA	19.93	Sales past 3/5Y	30.75% 51.31%	Gross Margin	85.78%	Volatility	5.24% 4.79%	Perf 5Y	-62.36%

Dividend TTM	-	EV/Sales	1.74	EPS Y/Y TTM	156.57%	Oper. Margin	5.61%	ATR (14)	3.21	Perf 10Y	-

Dividend Ex-Date	Jan 09, 2008	Quick Ratio	4.48	Sales Y/Y TTM	14.07%	Profit Margin	14.33%	RSI (14)	76.83	Recom	2.59

Dividend Gr. 3/5Y	-	Current Ratio	6.34	EPS Q/Q	0.00%	SMA20	24.25%	Beta	0.70	Target Price	61.08

Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	1.99%	SMA50	37.94%	Rel Volume	2.00	Prev Close	52.22

Employees	1,333	LT Debt/Eq	0.04	Earnings	Nov 02	SMA200	-6.45%	Avg Volume	1.16M	Price	64.14

IPO Date	May 03, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	136.32% 2.27%	Net Debt/EBITDA	-0.87	Volume	2,328,509	Change	22.83%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-04-26	Reiterated	RBC Capital	Sector Perform	$45 → $60
Aug-04-26	Reiterated	Stifel Nicolaus	Buy	$65 → $75
Aug-04-26	Reiterated	Robert W. Baird		$54 → $59
Aug-04-26	Reiterated	Piper Sandler	Neutral	$55 → $60
Aug-04-26	Upgrade	Oppenheimer	Perform → Outperform	$175 → $85
Aug-04-26	Reiterated	Truist Securities	Hold	$54 → $62
Aug-04-26	Reiterated	Evercore ISI Group	In Line	$40 → $54
Jul-28-26	Reiterated	UBS	Neutral	$67 → $39
Jul-16-26	Reiterated	Truist Securities	Hold	$50 → $54
Jun-23-26	Downgrade	Evercore ISI Group	Outperform → In Line	$55 → $40

Latest News

Aug-04-26

Aug-04-2602:01PM

Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Upzacks.com

10:00AM

Caterpillar, Wayfair, Zebra Technologies, Gartner And Other Big Stocks Moving Higher On TuesdayBenzinga

08:14AM

Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Resultsbenzinga.com

02:30AM

Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcriptseekingalpha.com

Aug-03-26

Aug-03-2608:05PM

Inspire Medical Systems Q2 Earnings Call Highlightsmarketbeat.com

07:01PM

Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metricszacks.com

06:46PM

Inspire Medical Systems (INSP) Q2 Earnings and Revenues Beat Estimateszacks.com

04:02PM

Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Planglobenewswire.com

Jul-29-26

Jul-29-2604:03AM

Inspire Medical Systems, Inc. $INSP Stake Boosted by Bank of Nova Scotiadefenseworld.net

Jul-28-26

Jul-28-2612:51PM

UBS Assumes Inspire Medical Systems at Sell, Lowers Price Target of $39Benzinga

Jul-27-26

Jul-27-2608:00AM

Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directorsglobenewswire.com

Jul-24-26

Jul-24-2605:55PM

Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSPbusinesswire.com

Jul-22-26

Jul-22-2608:00AM

Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directorsglobenewswire.com

Jul-20-26

Jul-20-2609:40AM

3 Medical Device Stocks Giving Investors a Different Healthcare Playmarketbeat.com

Jul-17-26

Jul-17-2611:51AM

Here's Why You Should Retain INSP Stock in Your Portfolio for Nowzacks.com

Company

Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	916	912	803	625	408	233	115	82	51
Cost of Goods Sold Incl. D&A	131	133	123	97	66	33	18	14	10
Gross Profit	785	779	680	528	342	200	98	68	41
Selling, General and Administrative Excl. Other	633	625	530	452	321	203	128	90	54
Research and Development	101	103	114	117	69	37	26	13	7
Other Operating Expense	0	0	0	-1	-1	0	0	0	0
Operating Income	52	51	36	-40	-48	-40	-56	-35	-20
Interest Expense	0	0	0	0	2	2	2	2	3
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	15	22	20	5	0	1	4	2
Net Income Before Taxes	64	66	58	-20	-44	-42	-57	-33	-22
Income Taxes	-67	-80	5	1	1	0	0	0	0
Consolidated Net Income	131	145	54	-21	-45	-42	-57	-33	-22
Net Income From Continuing Operations	131	145	54	-21	-45	-42	-57	-33	-22
Net Income	131	145	54	-21	-45	-42	-57	-33	-22
EPS (Recurring)	4.53	4.95	1.80	-0.72	-1.60	-1.54	-2.19	-1.40	-1.50
EPS (Basic, Before Extraordinaries)	4.53	4.95	1.80	-0.72	-1.60	-1.54	-2.19	-1.40	-1.50
EPS (Diluted)	4.49	4.89	1.75	-0.72	-1.60	-1.54	-2.19	-1.40	-1.50
EBITDA	80	80	65	-17	-41	-39	-54	-31	-18
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	14.29	18.86	105.93	—	—	—	—	—	—
Price To Sales Ratio	2.03	2.93	6.93	9.44	17.29	26.66	42.52	21.72	12.43
Gross Margin	85.70	85.42	84.68	84.48	83.82	85.84	85.22	82.93	80.39
Operating Margin	5.68	5.59	4.48	-6.40	-11.76	-17.17	-48.70	-42.68	-39.22
Net Margin	14.30	15.90	6.72	-3.36	-11.03	-18.03	-49.57	-40.24	-43.14
Shares Outstanding	29	29	30	29	28	27	26	24	15
Market Capitalization	1,860	2,675	5,561	5,899	7,053	6,212	4,890	1,781	634
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rondoni John	See Remarks	May 15 '26	Sale	43.28	2,641	114,302	27,165	May 19
Rondoni John	See Remarks	May 14 '26	Sale	43.01	700	30,107	29,806	May 15
mcCormick Shawn	Director	May 08 '26	Sale	45.31	696	31,536	27,712	May 11
Rondoni John	See Remarks	Jan 09 '26	Sale	100.00	109	10,900	13,797	Jan 12
mcCormick Shawn	Director	Dec 02 '25	Sale	139.00	1,200	166,800	24,846	Dec 04
mcCormick Shawn	Director	Nov 28 '25	Sale	127.48	2,000	254,960	26,046	Dec 01
Curet Myriam	Director	Aug 08 '25	Sale	77.28	4	309	3,365	Nov 24
Curet Myriam	Director	May 08 '25	Sale	153.22	2	306	3,369	Nov 24
Curet Myriam	Director	Apr 07 '25	Buy	148.26	1	148	3,371	Nov 24
Curet Myriam	Director	Mar 20 '25	Buy	163.84	4	655	3,370	Nov 24
Buchholz Richard	Chief Financial Officer	Aug 29 '25	Sale	93.39	11,000	1,027,290	44,867	Sep 02
Buchholz Richard	Chief Financial Officer	Aug 19 '25	Option Exercise	62.74	25,008	1,569,031	61,247	Aug 21
mcCormick Shawn	Director	Jun 04 '25	Option Exercise	16.00	4,000	64,000	28,046	Jun 06
Rondoni John	See Remarks	May 19 '25	Sale	149.38	1,734	259,025	13,766	May 21
mcCormick Shawn	Director	May 02 '25	Sale	160.00	360	57,600	24,046	May 05

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.